Connective Tissue Cancer

The FDA has approved Moleculin Biotech Inc's (NASDAQ: MBRX) request for Fast Track Designation for its drug, Annamycin, to treat soft tissue sarcoma (STS) lung metastases. The designation marks the second Fast Track status from the FDA for Annamycin. The company is focused on...